Home » Posts tagged with » Johnson & Johnson
Janssen secures DARZALEX FASPRO FDA approval for AL amyloidosis

Janssen secures DARZALEX FASPRO FDA approval for AL amyloidosis

DARZALEX FASPRO FDA approval for AL amyloidosis : Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has secured approval from the US Food and Drug Administration (FDA) for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd) for the treatment of light chain (AL) amyloidosis, which has been newly diagnosed in […]

Janssen seeks EMA’s expanded approval for DARZALEX in AL amyloidosis

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency (EMA) seeking the expanded approval for DARZALEX (daratumumab) in subcutaneous (SC) formulation to include the treatment of patients having light chain (AL) amyloidosis. Considered as a rare and potentially fatal disease, AL amyloidosis is due […]

Continue reading …
EC strikes deal for supply of JNJ-78436735 Covid-19 vaccine candidate

Johnson & Johnson (J&J) said that the European Commission (EC) has approved an advance purchase agreement for securing 200 million doses of the JNJ-78436735 Covid-19 vaccine candidate (Ad26.COV2.S) developed by its subsidiary Janssen Pharmaceutical Companies. Currently, the JNJ-78436735 vaccine candidate is being evaluated in the phase 3 ENSEMBLE Covid-19 vaccine trial across certain countries. The […]

Continue reading …
J&J begins phase 3 ENSEMBLE Covid-19 vaccine trial for JNJ-78436735

ENSEMBLE Covid-19 vaccine trial : Johnson & Johnson (J&J) has launched a multi-nation phase 3 trial called ENSEMBLE for its JNJ-78436735 Covid-19 vaccine candidate (Ad26.COV2.S), which is being developed by its subsidiary – Janssen Pharmaceutical Companies. The US healthcare giant said that the ENSEMBLE vaccine trial has been initiated following positive interim results from its […]

Continue reading …
Nipocalimab developer Momenta Pharmaceuticals to be acquired by J&J

J&J acquisition of Momenta Pharmaceuticals : US healthcare giant Johnson & Johnson (J&J) has signed a $6.5 billion deal to acquire Momenta Pharmaceuticals, a biotech company based in Cambridge, Massachusetts, which is focused on developing drugs for the treatment of rare immune-mediated diseases. As per the terms of the all-cash transaction, shareholders of Momenta Pharmaceuticals […]

Continue reading …
Janssen Covid-19 vaccine candidate Ad26.COV2.S bags $1bn deal from US govt

Johnson & Johnson (J&J) said that its subsidiary Janssen Pharmaceutical has agreed to manufacture and supply 100 million doses of its SARS-CoV-2 investigational vaccine Ad26.COV2.S to the US government, in a deal worth more than $1 billion. The Janssen Covid-19 vaccine candidate will be supplied either after approval by the US Food and Drug Administration […]

Continue reading …
Johnson & Johnson coronavirus vaccine targeted to be launched in early 2021

Johnson & Johnson said that it has selected a lead coronavirus vaccine candidate from constructs it has been working on since the start of this year, which it aims to bring it to the market in early 2021 through emergency use authorization. The company, in this connection, said that its subsidiary Janssen Pharmaceutical has significantly […]

Continue reading …
J&J takeover of Verb Surgical : J&J strikes deal with Verily for full ownership in robotic surgery company

J&J takeover of Verb Surgical : Johnson & Johnson (J&J) has agreed to take full ownership in US robotic surgery company Verb Surgical by acquiring the remaining stake it previously did not own from its joint venture partner Verily Life Sciences, an Alphabet company. The joint venture for the development of surgical robotic systems was […]

Continue reading …
Janssen to acquire skin disease drug candidate bermekimab from XBiotech

Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational compound for certain skin disorders, from XBiotech, in a deal worth up to $1.35 billion, as per the latest pharma acquisition news. Bermekimab, which is an anti-IL-1alpha monoclonal antibody (mAb), […]

Continue reading …
Janssen bags Stelara FDA approval for ulcerative colitis treatment

Stelara FDA approval for ulcerative colitis treatment : The Janssen Pharmaceutical Companies of Johnson & Johnson has bagged approval from the US Food and Drug Administration (FDA) for Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis. Considered to be a serious, chronic and progressive immune-mediated inflammatory disease of the large intestine, […]

Continue reading …
Page 1 of 212